Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Free Cash Flow (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Free Cash Flow for 13 consecutive years, with -$96.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 27.93% year-over-year to -$96.2 million, compared with a TTM value of -$373.3 million through Dec 2025, up 4.33%, and an annual FY2025 reading of -$373.3 million, up 4.33% over the prior year.
  • Free Cash Flow was -$96.2 million for Q4 2025 at Agios Pharmaceuticals, down from -$86.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$39.7 million in Q2 2021 and bottomed at -$163.2 million in Q3 2021.
  • Average Free Cash Flow over 5 years is -$89.4 million, with a median of -$85.5 million recorded in 2024.
  • Peak annual rise in Free Cash Flow hit 57.64% in 2021, while the deepest fall reached 906.68% in 2021.
  • Year by year, Free Cash Flow stood at -$89.3 million in 2021, then rose by 25.82% to -$66.3 million in 2022, then dropped by 10.86% to -$73.5 million in 2023, then crashed by 81.59% to -$133.4 million in 2024, then rose by 27.93% to -$96.2 million in 2025.
  • Business Quant data shows Free Cash Flow for AGIO at -$96.2 million in Q4 2025, -$86.8 million in Q3 2025, and -$78.5 million in Q2 2025.